长城医药科技六个月持有混合C(011674)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-31,142,490.08 |
174,705,061.77 |
152,226,087.80 |
-86,209,796.67 |
| 利息合计 |
79,699.88 |
270,562.96 |
150,793.01 |
409,518.08 |
| 其中:存款利息收入 |
79,699.88 |
270,562.96 |
150,793.01 |
409,518.08 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-7,477,891.70 |
163,450,480.85 |
41,196,548.88 |
-46,536,466.28 |
| 其中:股票投资收益 |
-7,764,276.66 |
161,886,641.68 |
40,065,233.32 |
-50,631,654.85 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
149,372.64 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
286,384.96 |
1,563,839.17 |
1,131,315.56 |
3,945,815.93 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-23,744,298.26 |
10,984,017.96 |
110,878,745.91 |
-40,082,848.47 |
| 其他收入 |
- |
- |
- |
- |
| 费用 |
2,705,816.66 |
6,837,676.48 |
3,108,172.11 |
6,319,482.64 |
| 管理人报酬 |
2,146,634.91 |
5,480,706.43 |
2,500,004.87 |
5,091,437.76 |
| 基金托管费 |
357,772.54 |
913,451.07 |
416,667.45 |
848,573.07 |
| 销售服务费 |
91,554.91 |
214,714.35 |
84,471.75 |
169,505.85 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
109,854.30 |
228,804.63 |
107,028.04 |
209,964.89 |
| 利润总额 |
-33,848,306.74 |
167,867,385.29 |
149,117,915.69 |
-92,529,279.31 |